Dna X (SONM) Net Income towards Common Stockholders (2018 - 2026)

Dna X's Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at $10.3 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 623.61% year-over-year to $10.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 22.86% YoY) and the FY2025 annual result came in at -$12.7 million, up 58.71% from the prior year.
• Net Income towards Common Stockholders was $10.3 million for Q1 2026 at Dna X, up from $3.5 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $12.7 million in Q4 2022 and bottomed at -$7.5 million in Q2 2025.
• A 5-year average of -$33235.3 and a median of -$1.3 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Peak annual rise in Net Income towards Common Stockholders reached 793.47% in 2024, while the deepest fall reached 1399.8% in 2024.
• Dna X's Net Income towards Common Stockholders stood at $12.7 million in 2022, then slumped by 110.13% to -$1.3 million in 2023, then jumped by 793.47% to $8.9 million in 2024, then plunged by 61.3% to $3.5 million in 2025, then surged by 197.28% to $10.3 million in 2026.
• Business Quant data shows SONM's Net Income towards Common Stockholders at $10.3 million in Q1 2026, $3.5 million in Q4 2025, and -$4.8 million in Q3 2025.